Becton Dickinson/$BDX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Becton Dickinson
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.
Ticker
$BDX
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
74,000
ISIN
US0758871091
Website
Becton Dickinson Metrics
BasicAdvanced
$51B
34.34
$5.16
0.38
$4.07
2.35%
Price and volume
Market cap
$51B
Beta
0.38
52-week high
$251.99
52-week low
$163.33
Average daily volume
2.7M
Dividend rate
$4.07
Financial strength
Current ratio
1.127
Quick ratio
0.483
Long term debt to equity
69.989
Total debt to equity
76.344
Dividend payout ratio (TTM)
76.77%
Interest coverage (TTM)
5.33%
Profitability
EBITDA (TTM)
5,573
Gross margin (TTM)
46.32%
Net profit margin (TTM)
7.18%
Operating margin (TTM)
15.28%
Effective tax rate (TTM)
10.99%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
3.67%
Return on equity (TTM)
5.89%
Valuation
Price to earnings (TTM)
34.336
Price to revenue (TTM)
2.455
Price to book
2.01
Price to tangible book (TTM)
-4.48
Price to free cash flow (TTM)
19.773
Free cash flow yield (TTM)
5.06%
Free cash flow per share (TTM)
896.55%
Dividend yield (TTM)
2.30%
Forward dividend yield
2.35%
Growth
Revenue change (TTM)
5.84%
Earnings per share change (TTM)
14.07%
3-year revenue growth (CAGR)
3.31%
10-year revenue growth (CAGR)
9.46%
3-year earnings per share growth (CAGR)
-6.58%
10-year earnings per share growth (CAGR)
-0.54%
3-year dividend per share growth (CAGR)
5.39%
10-year dividend per share growth (CAGR)
5.68%
What the Analysts think about Becton Dickinson
Analyst ratings (Buy, Hold, Sell) for Becton Dickinson stock.
Bulls say / Bears say
Becton Dickinson's acquisition of Edwards Lifesciences' critical care products unit for $4.2 billion is expected to enhance its product portfolio and drive revenue growth. (reuters.com)
Analysts have set a 12-month stock price forecast of $231.5 for BDX, indicating a potential upside of 36.20% from the latest price. (stockanalysis.com)
BDX has been increasing its dividend for 53 consecutive years, demonstrating a strong commitment to returning value to shareholders. (marketbeat.com)
BDX settled charges with the SEC over misleading investors about risks associated with its Alaris infusion pump, agreeing to pay a $175 million civil penalty. (reuters.com)
The company canceled a €206 million investment in a syringe manufacturing plant in Zaragoza, Spain, leading to layoffs and potential reputational damage. (cadenaser.com)
BDX's debt-to-equity ratio decreased to 0.35 in Q4 2024 from 0.75 in Q3 2024, indicating reduced reliance on debt financing, but the company's return on equity also declined to 0.01, suggesting lower profitability. (siriusinvestors.com)
Data summarised monthly by Lightyear AI. Last updated on 2 Jul 2025.
Becton Dickinson Financial Performance
Revenues and expenses
Becton Dickinson Earnings Performance
Company profitability
Becton Dickinson News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Becton Dickinson stock?
Becton Dickinson (BDX) has a market cap of $51B as of July 04, 2025.
What is the P/E ratio for Becton Dickinson stock?
The price to earnings (P/E) ratio for Becton Dickinson (BDX) stock is 34.34 as of July 04, 2025.
Does Becton Dickinson stock pay dividends?
Yes, the Becton Dickinson (BDX) stock pays dividends to shareholders. As of July 04, 2025, the dividend rate is $4.07 and the yield is 2.35%. Becton Dickinson has a payout ratio of 76.77% on a trailing twelve-month basis.
When is the next Becton Dickinson dividend payment date?
The next Becton Dickinson (BDX) dividend payment date is unconfirmed.
What is the beta indicator for Becton Dickinson?
Becton Dickinson (BDX) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.